Shenzhen JYMed Technology Co., Ltd.

Primary study objective: To compare the pharmacokinetics (PK) of semaglutide injection and Novota® after a single subcutaneous injection in healthy Chinese subjects, and to evaluate the similarity of PK characteristics between the two preparations. Secondary study objective: To evaluate the safety of semaglutide injection and Novota® after a single subcutaneous injection in healthy Chinese subjects.

Primary objective: To evaluate the tolerability and safety of lepsulotide acetate oral lyophilized powder in the treatment of active mild ulcerative colitis Secondary objective: To investigate the pharmacokinetic characteristics of LH025 in patients with active mild ulcerative colitis; To study the effectiveness of LH025 in the treatment of patients with active mild ulcerative colitis Exploratory objective: To explore the relationship between the pharmacokinetic and pharmacodynamic indicators of LH025 in patients with active mild ulcerative colitis

Main purpose: To conduct a pharmacokinetic comparison study in healthy volunteers using liraglutide injection produced by Shenzhen Jianxiang Biopharmaceutical Co., Ltd. as the test preparation and liraglutide injection (trade name: Novo®) produced by Novo Nordisk of Denmark as the reference preparation to evaluate the similarity of their pharmacokinetic characteristics. Secondary purpose: To evaluate the similarity of immunogenicity and safety of a single injection of the test preparation and the reference preparation (trade name: Novo®) in healthy volunteers.